Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree
It should not be combined with other GLP-1based weight-loss agents or medications used to treat insulin-mediated conditions, as this combination may significantly increase the risk of hypoglycemia (dangerously low blood sugar levels)
shows robust anti-obesity, anti-diabetic, and cardiometabolic effects in preclinical and clinical studies, including significant reductions in body weight, glycemic markers, blood pressure, and lipids 1,3,5
What does GIP receptor co-agonism add in preclinical models
How the Telehealth Structure Works: Platform, Clinician, and Pharmacy One of the most common points of confusion with telehealth prescription services is understanding who actually does what